SGD Pharma Announces High-Performance Rebuild of Saint-Quentin-Lamotte Furnace
SGD Pharma has announced a high performance rebuild of one of our two furnaces at the Saint-Quentin-Lamotte (SQLM) manufacturing plant in France. This rebuild is part of our ambitious global decarbonization strategy and will contribute to a two-thirds reduction in our total carbon emissions by 2040.
This project, which will cut the SQLM CO2 emissions by almost 20%, will have two phases that both reduce the consumption of natural gas while increasing the use of electricity on site.
The SQLM furnace rebuild accelerates the electrification of one of the two furnaces (yielding a 40% increase in electricity output), the other furnace already being 100% electric for many years. The project will also deliver a 50% reduction of gas consumption in the forehearths.
This ambitious investment project is partly financed by the French government as part of France 2030, (operated by ADEME) and in part by the European Union - Nextgenerationeu/REPOWEREU.
